DEALS
Zhong Lun Advises on Adlai Nortye' IPO on Nasdaq
Zhong Lun Advises on Adlai Nortye' IPO on Nasdaq
Release time：2023-10-11
Voice Announcements
On September 29, 2023, Adlai Nortye Ltd. (“Adlai Nortye") announced its initial public offering on Nasdaq (Nasdaq: ANL), expecting to raise USD 97.5 million. The total offering size will be up to USD 106.1 million upon full exercise of the over-allotment option. Cantor Fitzgerald & Co. acted as the sole bookrunner for this offering. This offering is the first of its kind where the company concerned has completed the CSRC filing as per requirements of the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies and launched its initial public offering in the US.
As a global clinical-stage biotechnology company, Adlai Nortye has developed a robust pipeline of product candidates through collaborations and internal discoveries, with multi-national R&D centers established in the US and China. Under its mission to transform cancers into manageable chronic, and eventually curable, diseases, Adlai Nortye focuses on the discovery and development of innovative cancer therapies for patients across the spectrum of tumor types in China and globally.
Zhong Lun Law Firm acted as the PRC legal advisor to the bookrunner in this offering. The legal team from Zhong Lun was led by partner Liqiong Wang, and team members also included non-equity partner Simon Xu and associates Yulin Ma, Evelyn Ni and Annan Tu.
Professionals
-
-
Liqiong WANG
Equity Partner
ShanghaiPractices： Hong Kong & Overseas Capital Markets,Chinese Mainland Capital Markets,Private Equity & Investment FundsIndustries： Real Estate,Transportation & Logistics,Healthcare,Pharmaceuticals & Life Sciences,Education & Training -
Liqiong WANG
Equity Partner
Shanghai
-
